Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Darbepoetin alfa Stories

2009-10-30 19:44:00

THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. The study, published online today in the New England Journal of Medicine and presented at the...

2009-09-17 14:55:00

WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ -- Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells). While certain treatments can help manage the symptoms of anemia, some studies have suggested that they may lead to complications. A new study, however, demonstrates that MDS patients with anemia may benefit from treatment...

2009-08-25 15:12:00

THOUSAND OAKS, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either...

2009-05-15 08:29:00

New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, Calif., May 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present new data from the Company's oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting...

2009-05-13 14:45:00

HORSHAM, Pa., May 13 /PRNewswire/ -- Data from a study of managed-care cancer patients receiving chemotherapy and newly treated with erythropoiesis-stimulating agents (ESAs) found that the cumulative ESA cost with Epoetin alfa (EPO) was 29 percent lower than treatment with darbepoetin alfa (DARB). The analysis, published in the Spring issue of the Journal of Medical Economics, was sponsored by Centocor Ortho Biotech Services, LLC. The retrospective cohort study of 10,928 patients...

2009-05-02 07:31:43

Erythropoiesis-stimulating agents not recommended as routine therapy The use of drugs to encourage red blood cell formation (erythropoiesis-stimulating agents) in cancer patients with anemia increases the risk of death and serious adverse events such as blood clots, found a new study in CMAJ. While the relative increased risk of death was only 15-16%, because of the high mortality rates in cancer patients this increase might translate into significant numbers of people. "These findings...

2009-04-27 20:00:00

EXTON, Pa., April 27 /PRNewswire/ -- BioTrends Research Group, Inc. released TreatmentTrends(R): US Nephrology, a syndicated report based on online survey results from over 200 US Nephrologists. In the ESA market, changes that have occurred seem to have taken place at the product level, while the overall use of ESAs has remained stable compared to the same period last year. Among patients with Chronic Kidney Disease not on dialysis (CKD), market share for Ortho Biotech's Procrit has been...

2008-12-01 19:55:00

EXTON, Pa., Dec. 1 /PRNewswire/ -- BioTrends Research Group, Inc. released its third TreatmentTrends(TM): European Nephrology Report. This report runs parallel to two ongoing studies BioTrends conducts -- TreatmentTrends(TM): US and Canadian Nephrology. The report is based on the results of an on-line survey completed by 200 Nephrologists from the UK, Germany, France, Italy, and Spain. The focus is on the management of renal anemia and hyperphosphatemia. In the ESA market, Amgen's Aranesp...

2008-11-25 11:59:01

Blood transfusions used to treat anemia in patients with cancer are associated with an increased risk of life-threatening blood clots, U.S. researchers say. Scientists at the University of Rochester Medical Center in New York say the findings pose a quandary for doctors who want to prevent thromboembolism -- a blood clot that breaks loose and is carried by the blood stream causing a stroke or pulmonary embolism -- one of the leading causes of illness and death in people with cancer. Lead...

2008-11-13 09:00:37

Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States. "With our non-dialysis trials, PEARL 1 and 2, as well as our dialysis trial, EMERALD 1, fully enrolled, we have now completed enrollment in...